Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept

NCT04287348 is registered in ClinicalTrials.gov with Vista Klinik as lead sponsor.

NCT NCT04287348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04287348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept
Lead sponsor
Vista Klinik
Phase
Phase 4
Overall status
Terminated
Start date
July 20, 2020
Completion date
November 22, 2021
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration